Neogenomics Inc
NASDAQ:NEO

Watchlist Manager
Neogenomics Inc Logo
Neogenomics Inc
NASDAQ:NEO
Watchlist
Price: 16.39 USD 6.5% Market Closed
Market Cap: 2.1B USD
Have any thoughts about
Neogenomics Inc?
Write Note

Neogenomics Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Neogenomics Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Neogenomics Inc
NASDAQ:NEO
Long-Term Debt
$340m
CAGR 3-Years
-14%
CAGR 5-Years
29%
CAGR 10-Years
52%
Thermo Fisher Scientific Inc
NYSE:TMO
Long-Term Debt
$31.2B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
11%
Danaher Corp
NYSE:DHR
Long-Term Debt
$16.3B
CAGR 3-Years
-12%
CAGR 5-Years
0%
CAGR 10-Years
19%
Mettler-Toledo International Inc
NYSE:MTD
Long-Term Debt
$1.9B
CAGR 3-Years
5%
CAGR 5-Years
11%
CAGR 10-Years
18%
Agilent Technologies Inc
NYSE:A
Long-Term Debt
$2.1B
CAGR 3-Years
-8%
CAGR 5-Years
11%
CAGR 10-Years
0%
IQVIA Holdings Inc
NYSE:IQV
Long-Term Debt
$12.3B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
20%
No Stocks Found

Neogenomics Inc
Glance View

Market Cap
2.1B USD
Industry
Life Sciences Tools & Services

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,000 full-time employees. The company went IPO on 2012-12-10. The firm operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. The company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. The company operates testing laboratories in United States, Europe and Asia.

NEO Intrinsic Value
12.26 USD
Overvaluation 25%
Intrinsic Value
Price

See Also

What is Neogenomics Inc's Long-Term Debt?
Long-Term Debt
340m USD

Based on the financial report for Sep 30, 2024, Neogenomics Inc's Long-Term Debt amounts to 340m USD.

What is Neogenomics Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
52%

Over the last year, the Long-Term Debt growth was -37%. The average annual Long-Term Debt growth rates for Neogenomics Inc have been -14% over the past three years , 29% over the past five years , and 52% over the past ten years .

Back to Top